U

University of North Carolina at Chapel Hill | Institute of Global Health and Infectious Disease

Research site
(Unclaimed)
Location
720 Martin Luther King, Jr. Blvd., Chapel Hill, North Carolina, United States of America
Site insights

Top conditions

Carcinoma (9 trials)

Syndrome (5 trials)

Transitional Cell Carcinoma (3 trials)

Urinary Bladder Cancer (3 trials)

Adenocarcinoma (3 trials)

Top treatments

Pembrolizumab
Platinum
DNL126
R-CHP
LY2835219
Doxorubicin
MK-6482-005
Sotatercept
Durvalumab
Belzutifan

Parent organization

This site is a part of University of North Carolina at Chapel Hill

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trials

31 of 67
Status: Active
Trial type: Interventional
Funder type: Industry

Filters
3
A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors

TScan Therapeutics is developing cellular therapies across multiple solid tumors in which autologous participant-derived T cells are engineered to ex...

Enrolling
HPV-Related Carcinoma
Melanoma
Biological: TSC-204-C0702
Biological: TSC-200-A0201

This Phase III, randomized, double-blind, placebo-controlled study will compare the efficacy, safety, and pharmacokinetics of polatuzumab vedotin plu...

Active, not recruiting
Diffuse Large B-Cell Lymphoma
Drug: Polatuzumab vedotin Placebo
Drug: Vincristine Placebo

This is an open label Phase 1b/2 study to evaluate the efficacy and safety of ACR-368 as monotherapy or in combination with ultralow dose gemcitabine...

Enrolling
Endometrial Adenocarcinoma
Urothelial Carcinoma
Drug: ACR-368
Diagnostic Test: OncoSignature

The primary objective of this study is to compare belzutifan to everolimus with respect to progression-free survival (PFS) per Response Evaluation Cr...

Active, not recruiting
Carcinoma, Renal Cell
Drug: Everolimus
Drug: Belzutifan

The purpose of this study is to evaluate the efficacy and safety of guselkumab in participants with moderately to severely active ulcerative colitis...

Active, not recruiting
Ulcerative Colitis
Drug: Guselkumab
Drug: Placebo

The main purpose of this study is to learn more about the safety, side effects, and effectiveness of LOXO-435. LOXO-435 may be used to treat cancer o...

Enrolling
Urinary Bladder Neoplasms
Neoplasm Metastasis
Drug: LOXO-435
Drug: Pembrolizumab

This study evaluates the safety of abemaciclib in combination therapies (letrozole, anastrozole, tamoxifen, exemestane, exemestane plus everolimus, t...

Active, not recruiting
Breast Neoplasms
Drug: Fulvestrant
Drug: Pertuzumab

This is an open-label, multi-center Phase 1/2 study of oral LOXO-305 (pirtobrutinib) in patients with CLL/SLL and NHL who have failed or are intolera...

Active, not recruiting
Waldenstrom Macroglobulinemia
Marginal Zone Lymphoma
Drug: Venetoclax
Drug: Rituximab

TAK-981 is being tested in combination with pembrolizumab to treat participants who have select advanced or metastatic solid tumors.The study aims ar...

Active, not recruiting
Advanced or Metastatic Solid Tumors
Drug: Pembrolizumab
Drug: TAK-981

The primary objectives of the study are to evaluate the efficacy of BIIB059 (litifilimab) compared with placebo in reducing skin disease activity mea...

Enrolling
Subacute Cutaneous Lupus Erythematosus
Chronic Cutaneous Lupus Erythematosus
Drug: BIIB059 (litifilimab)
Drug: Placebo

This extension study of HGT-HIT-045 is designed to collect long-term safety data in pediatric participants with Hunter syndrome and cognitive impairm...

Active, not recruiting
Hunter Syndrome
Drug: Idursulfase-IT
Drug: Elaprase

The purpose of this study is to evaluate the safety and tolerability of extended dosing with eplontersen in participants with ATTR-CM.

Enrolling
Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)
Drug: Eplontersen

This is a multi-center, pivotal study to assess the safety and effectiveness of a new method of treating severe burns using NovoSorb® Biodegradable T...

Enrolling
Burns
Procedure: Standard of Care
Device: NovoSorb BTM

The purpose of this research study is to determine how well an FDA-approved drug, dupilumab, works to treat patients with severe strictures and activ...

Not yet enrolling
EoE
Eosinophilic Esophagitis
Drug: Dupilumab

The goal of this clinical trial is to evaluate the effects of using the SinuSonic on psychological and physical well-being in adults who have nasal/s...

Enrolling
Nasal Congestion and Inflammations
Sinus Congestion Chronic
Other: SinuSonic

The purpose of this trial is to investigate the PK, PD, safety, and activity of efgartigimod IV in children and adolescents aged from 2 to less than...

Enrolling
Generalized Myasthenia Gravis
Biological: Efgartigimod IV

This randomized trial will evaluate the effect of fenofibrate compared with placebo for prevention of diabetic retinopathy (DR) worsening through 6 y...

Enrolling
Diabetic Retinopathy
Other: Placebo
Drug: Fenofibrate

IMGN853-0420 is a multicenter, open-label, phase 2 study of carboplatin plus mirvetuximab soravtansine followed by mirvetuximab soravtansine continua...

Enrolling
Primary Peritoneal Cancer
High Grade Ovarian Cancer
Drug: Mirvetuximab soravtansine
Drug: Carboplatin
Locations recently updated

The purpose of this study is to characterize the safety, tolerability, PK, and efficacy of INCB 99280 in combination with ipilimumab in participants...

Enrolling
Melanoma
Renal Cell Carcinoma (RCC)
Drug: INCB 99280 with Ipilimumab

The purpose of this study is to evaluate the long-term safety and efficacy of pembrolizumab (MK-3475) in participants from previous Merck pembrolizum...

Enrolling
Solid Tumors
Hematologic Malignancies
Drug: Pembrolizumab
Drug: Lenvatinib

Trial sponsors

University of North Carolina (UNC) logo

University of North Carolina (UNC) (15 trials)

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems